SEngine Precision Medicine

Executive Summary

SEngine Precision Medicine, based in Seattle and founded in 2015, is pioneering functional precision oncology through its patient-derived organoid (PDO) platform. The company’s proprietary technology creates living tumor avatars from individual patients’ biopsies, enabling real-time testing of dozens of approved and investigational drugs outside the body. By generating a personalized drug sensitivity profile, SEngine aims to overcome the limitations of genomic-only testing, which often fails to capture the complex biology of a tumor. The platform has shown promise in retrospective studies, accurately predicting which therapies will be effective and which will fail, thereby avoiding ineffective treatments and toxic side effects. With the rise of precision medicine and growing demand for evidence-based treatment selection, SEngine’s approach addresses a critical unmet need in oncology: matching the right drug to the right patient at the right time. The company is positioned to transform standard-of-care decision-making, particularly in hard-to-treat cancers such as pancreatic, ovarian, and rare tumors where genomic insights are insufficient. Looking ahead, SEngine is advancing toward clinical validation and commercialization. The company is conducting prospective trials to establish the clinical utility of its PDO-guided therapy in multiple cancer types. Success could unlock partnerships with pharmaceutical firms seeking to optimize clinical trial enrollment or identify responders for targeted agents. SEngine’s platform may also serve as a powerful tool for drug development, enabling rapid assessment of compound efficacy in patient-representative models. While still a private company with limited public funding history, its recent enrollment in accelerator programs and growing peer-reviewed evidence suggest momentum. The key to scaling will be demonstrating robust clinical outcomes, achieving reimbursement coverage, and building partnerships that integrate its tests into oncology workflows. If these milestones are met, SEngine could become a leading player in the functional precision diagnostics space.

Upcoming Catalysts (preview)

• Q4 2026Publication of prospective clinical validation trial results in major cancer types (e.g., pancreatic, ovarian)60% success
• H2 2026Strategic partnership with a large pharmaceutical company for drug development or co-diagnostic collaboration45% success
• Q3 2026Series A or B funding round to support commercial launch and scaling of operations70% success